Lilly, meanwhile, has been selling its GLP-1 agonist Trulicity (dulaglutide) in China since 2019, while its dual GLP-1/GIP agonist tirzepatide was approved for diabetes in May and for obesity just ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

AS GLP-1 AGONISTS soar in popularity—about 12 percent of the U.S. population has tried one, most often Ozempic or Wegovy ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...